Photodynamic therapy of human ocular cancer.
Photodynamic therapy (PDT), also known as photoradiation therapy, was employed in five patients with ocular tumors that had been photosensitized to hematoporphyrin derivative (HPD). In each case more conventional treatment had failed to control the tumor, or the patient was considered a poor candidate for surgical intervention because of advanced age or general health. Intravenous administration of 2.5-3.0 mg/kg HPD was followed by PDT 2-4 days later, using a dye laser tuned to a wavelength of 632 nm. Laser light was delivered either by a fiber optic probe maintained at a fixed distance, or via a slit lamp system, for intervals of up to 20 minutes. The levels of energy applied were mainly below 420 Joules/cm2, but for tumors less than 1 mm diameter energy levels were as high as 3000 J/cm2 with a conservative power value as low as 20 mW/cm2. Tumor response to PDT was disappointing. Although substantial superficial tumor necrosis occurred in several cases, it did not extend to the deeper levels of tumor tissue. In each instance surgical intervention became necessary. Deficiencies in the procedure are discussed.
D000368:Aged; D002675:Child, Preschool; D005134:Eye Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D017324:Hematoporphyrin Derivative; D006415:Hematoporphyrins / Q000627:therapeutic use*; D006801:Humans; D010778:Photochemotherapy
D006415:Hematoporphyrins; D017324:Hematoporphyrin Derivative